Health Canada accepts semaglutide 2.4 mg, a GLP-1RA treatment for MASH, as a supplemental New Drug Submission under the Priority Review Policy
It is estimated that by 2030 the prevalence of MASH (Metabolic Dysfunction-Associated Steatohepatitis) in the Canadian general population will increase from 5.2% to 6.5%. 1
Left untreated, MASH can progress to serious and even fatal outcomes, such as cirrhosis, liver cancer, and the need for liver transplant. 2
MISSISSAUGA, ON, May 2, 2025 /CNW/ - Today, Novo Nordisk Canada announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental new drug submission (sNDS) for semaglutide 2.4 mg, a once weekly therapy for people living with MASH (metabolic dysfunction-associated steatohepatitis).
"Semaglutide 2.4 mg represents a therapeutic advancement for patients living with MASH, addressing a critical unmet medical need," says Vince Lamanna, President of Novo Nordisk Canada Inc. "Health Canada's acceptance of the Semaglutide 2.4 mg submission for review brings us one step closer to providing the first treatment option for eligible people living with MASH."
About semaglutide 2.4 mg
Semaglutide injection 2.4 mg is currently approved by Health Canada for chronic weight management and non-fatal myocardial infarction (MI) risk reduction in adults with established cardiovascular disease and BMI ≥ 27 kg/m 2. 3
Semaglutide is not approved in Canada for the treatment of MASH. Safety and efficacy are not established, and there is no guarantee that semaglutide will become commercially available for this use under clinical investigation.
About Metabolic Dysfunction-Associated Steatohepatitis (MASH)
MASH is a chronic, progressive metabolic disease affecting the liver, which can be potentially life-threatening if not properly managed. 4, 5 Among people who are living with overweight or obesity, approximately one in three also have MASH. 6 Excess fat can build up in the liver, which, over time, can lead to inflammation and severe scarring of the liver. 7 People living with MASH often experience few or no specific symptoms in the early stages of the disease, which often results in a delayed diagnosis. 8 It is estimated that by 2030 the prevalence of MASH in the Canadian general population will increase from 5.2% to 6.5%. 1 In Canada, the number of deaths are expected to double in people living with MASH by 2030. 1
About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 76,300 people in 80 countries and markets its products in around 170 countries. For more information, visit novonordisk.ca, Facebook, Instagram, X, LinkedIn and YouTube.
SOURCE Novo Nordisk Canada Inc.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
37 minutes ago
- Toronto Star
Teva birth control pills recalled across Canada over extra placebos
Birth control medication is being pulled from Canadian shelves over extra placebo tablets, Health Canada says. The recall concerns Teva Canada's Seasonale tablet with lot numbers 100059661 and 100069150, according to the agency's recall notice. Health Canada is urging patients not to skip doses or stop taking their birth control. But if your package contains white placebo pills in the first or second blister card tray, don't take them, and return the pills to your pharmacy for a replacement. ARTICLE CONTINUES BELOW If you can't get to a pharmacy right away, take the next pink active pill in the proper order, as laid out in the instructions, until you can get a replacement. If you took a white placebo pill instead of an active pink pill from one of the first two trays, or if you are unsure, you should also use another method of non-hormonal contraception and consult with your health care professional.
Toronto Star
an hour ago
- Toronto Star
3 Canadian national team players among the Whitecaps stricken by illness
Three Canadian national team players were among those who fell ill following the Vancouver Whitecaps' appearance in the CONCACAF Champions Cup final last weekend in Mexico City. The Whitecaps said a 'significant number' of players and staff had a gastrointestinal illness. Three of them — Ali Ahmed, Sam Adekugbe and Jayden Nelson — were ill when they arrived at Canada's training camp in Halifax ahead of Saturday's Canadian Shield match against Ukraine, coach Jesse Marsch said Friday.
Cision Canada
3 hours ago
- Cision Canada
Public Advisory - Health Canada warns consumers not to inhale nitrous oxide, also known as laughing gas, recreationally Français
Product: Various nitrous oxide products Issue: Health products – Product safety; Unauthorized product What to do: Do not inhale nitrous oxide products for recreational purposes. If you use prescription nitrous oxide recreationally and experience side effects, seek medical attention immediately. Affected products Various nitrous oxide products. Examples of seized products include: Bamboozle Need Whip Primewhip Primewhip XL Space Gas Issue Health Canada is warning consumers about the serious health risks, including death, of inhaling nitrous oxide products, also known as laughing gas and by various street names, such as "whippets," "hippy crack," "NOS" and "nang," for recreational purposes. In Canada, nitrous oxide sold for inhalation is a drug and can only be administered by an authorized health care professional for legitimate and safe uses, such as in medical and dental procedures for sedation and pain relief. It is also in cream dispensers and other food tools where it is not meant to be inhaled. When inhaled—or "huffed" —nitrous oxide can cause euphoria and relaxation. It can also cause serious adverse effects such as: loss of consciousness and in some cases, death birth defects anemia, vitamin B12 deficiency impaired bowel and bladder function confusion, agitation, delusions, hallucinations, paranoia and depression increased heart rate, palpitations, low blood pressure, heart attack and stroke lack of oxygen in the body (asphyxia), blood clots in the extremities and in the lungs, and air leaks into the space between the lung and chest wall (pneumothorax) tingling, numbness and weakness of the limbs and extremities (fingers and toes), uncoordinated walking and falls nerve damage, spinal cord degeneration, prolonged pain and, in severe cases, permanent paralysis Repeated use increases the likelihood of severe outcomes and may result in lasting neurological damage, even after stopping use. Regular use can also lead to addiction and withdrawal symptoms. Advertising and selling nitrous oxide products for inhalation to the public is strictly prohibited. However, Health Canada is aware that these products are being sold online and in retail stores. These products may be deceptively labelled: as "whip cream chargers," in flavours, which are not permitted, in stores you would not expect to find whipped cream chargers; and in large containers you would not expect for dispensing whipped cream. Health Canada has not reviewed these products, which are regulated as drugs, for safety, efficacy or quality. Also, they could be contaminated in ways that create additional health risks when inhaled. Health Canada strongly advises that consumers not inhale any nitrous oxide products for recreational purposes. Health Canada has seized several unauthorized nitrous oxide products and has worked with Canada Border Services Agency (CBSA) to stop unauthorized shipments from entering the country. The Department will continue to take action to stop the sale of unauthorized products and to work with CBSA to help prevent further importations. What you should do
